Otsuka Pharmaceutical Development & Commercialization, Inc.

This study tests a drug called sibeprenlimab for people with Sjögren's disease, an autoimmune condition that causes dryness and fatigue. About 83 adults will receive injections every 4 weeks to see if it reduces disease activity. The goal is to control symptoms, not cure the dise…

This study was designed to test an experimental drug called OPC-131461 in people hospitalized for worsening heart failure who still had signs of fluid buildup after initial treatment. The goal was to see if the drug could improve a key heart stress marker (NT-proBNP) over 30 days…

This study planned to test the drug tolvaptan in very young infants (28 days to under 12 weeks old) with a rare, severe kidney disease called ARPKD. The goal was to see if the drug could delay or prevent the need for dialysis or a kidney transplant in the first year of life. Howe…

This phase 3 trial tests a drug called sibeprenlimab for people with IgA nephropathy, a kidney disease that can lead to kidney failure. About 530 adults are receiving either the drug or a placebo to see if it reduces protein in urine and slows kidney function decline. The goal is…

This study tests the long-term safety and effectiveness of sibeprenlimab, an experimental drug, in about 600 adults with IgA nephropathy—a kidney disease that can lead to kidney failure. Participants must have completed a prior sibeprenlimab study and may benefit from continued t…